Details for Patent: 8,204,763

Summary for Patent: 8,204,763

Title:	Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
Abstract:	Novel methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug. Embodiments are provided in which the involved prescribers, pharmacies and patients are registered in one or more computer databases. Embodiments are also provided in which registered patients receive counseling information concerning the risks attendant to foetal exposure to the drug. Male patients and female patients who are not pregnant may, in certain circumstances, receive the drug.
Inventor(s):	Elsayed; Marc (Bridgewater, NJ), Williams; Bruce (Flemington, NJ)
Assignee:	Celgene Corporation (Summit, NJ)
Application Number:	12/966,240
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,204,763
Patent Claim Types: see list of patent claims	Use;
Scope and claims summary:	Combinatorial Library of Chimeric Antigen Receptor (CAR) Constructs for Immune Therapy United States Patent 8204763, titled "Combinatorial Library of Chimeric Antigen Receptor (CAR) Constructs for Immune Therapy," grants various significant aspects of combinatorial libraries for the production of chimeric antigen receptor (CAR) constructs. The CAR constructs are genetically engineered immune cells designed to target and eliminate cancerous cells. The patent outlines the scope of combinatory libraries that enable the creation of diverse CAR constructs. The patent claims cover the following key areas: Compositions and methods for generating a combinatorial library of CAR constructs, comprising segments encoding specific antigen-binding sites and spacer sequences for optimal antigen presentation and T-cell activation. Specific target antigens identified for CAR constructs, such as tumor-associated antigens, bacterial, viral, fungal, or parasitic pathogens, and disease-specific antigens. Incorporation of various signaling domains from distinct families (e.g., CD28, OX40, 41BB, CD27, and 4-1BBL) at the carboxyl terminus of the CAR construct to enhance T-cell activation and proliferation. Approaches to select and characterize CAR constructs with improved efficacy, specificity, and persistence from in vitro-selected libraries or the immune system, using techniques such as ELISA, RT-PCR, and flow cytometry. Reasons for Patent Value: 1. Breakthrough in Developing Therapeutic Agents: Patent 8204763 addresses pressing medical requirements by providing designs for creating more customized, effective, and long-lasting CAR constructs with precise targets for effective immune therapy. 2. Flexibility and Versatility of Immunotherapies: Varying the antigen-binding regions of CAR constructs can allow the selection of different target cells, providing flexibility for practitioners to tackle diverse disease conditions, whether related to infections or diseases. 3. Future Promises: Applications that incorporate a genetically modified immune system to fight cancer often have considerable promise for patients with relapsed or refractory disease, generating increased interest in combinatorial library methodology.

Drugs Protected by US Patent 8,204,763

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate